Clinical Stem Cell Center, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210000, People's Republic of China.
Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, 210000, People's Republic of China.
Stem Cell Res Ther. 2020 May 13;11(1):176. doi: 10.1186/s13287-020-01696-6.
Cell-based therapy products are supposed to be the most complex medicine products in the history of human medical care. In this study, we established a safety evaluation system for therapeutic stromal cells based on the existing regulations and current testing techniques to provide general quality requirements for human umbilical cord mesenchymal stromal cell (HUCMSC) therapy product.
In this system, we comprehensively evaluate the environmental monitoring program, quality control of critical raw materials and reagents, donor screening criteria, cell safety, quality, and biological effects, not only in line with the basic criteria of biological products, but also following the general requirements of drugs.
The qualified HUCMSCs were tested for various clinical researches in our hospital, and no severe adverse reaction was observed in 225 patients during a 1-year follow-up period.
In this study, we establish a systemic quality control and potent assays to guarantee the safety and effectiveness of HUCMSCs based on a minimum set of standards in MSC-based product.
细胞治疗产品被认为是人类医疗保健史上最复杂的药物产品。在本研究中,我们基于现有法规和当前检测技术,建立了治疗性基质细胞的安全性评估体系,为人脐带间充质基质细胞(HUCMSC)治疗产品提供了一般质量要求。
在该体系中,我们全面评估环境监测方案、关键原材料和试剂的质量控制、供体筛选标准、细胞安全性、质量和生物学效应,不仅符合生物制品的基本标准,而且遵循药物的一般要求。
合格的 HUCMSCs 在我院进行了各种临床研究,225 例患者在 1 年随访期间未观察到严重不良反应。
本研究建立了系统的质量控制和有效检测方法,以保证 HUCMSC 的安全性和有效性,该方法基于 MSC 产品的最低标准集。